



---

ASX Announcement and Media Release

(ASX : SIE)

**SciGen Ltd and its Polish Holding Company Bioton S.A. sign agreement with Bayer Schering Pharma in China**

**Singapore, July 10th, 2009.** – SciGen Ltd (“SciGen”)and its Polish holding company, Bioton SA (“Bioton”) have signed an exclusive supply and distribution agreement (“S & D agreement”). with Bayer Schering Pharma AG (“Bayer”). The agreement is to realise the group’s strategic goal of expansion of the insulin franchise through alliances with blue-chip pharma companies on most important global markets.

Following execution of the S & D agreement SciGen entered into a profit sharing agreement with Bioton. Under the profit sharing agreement SciGen will receive a share of the revenues from the S & D agreement with Bayer. This new series of agreements are expected to be more beneficial for SciGen than its previous distribution agreement in China.

*“With this agreement for long-term collaboration Bioton has materialized one of its strategic goals to develop its strong international position on growing insulin markets via alliances with leading pharmaceutical companies. We emphasize our position as a recognized leader in insulin production. Bayer is our partner of choice.”, said Janusz R. Guy, CEO of Bioton S.A.*

*“Today, Bayer is already a top ranking international pharmaceutical company in China with our pharmaceutical product Glucobay® for the treatment of type 2 diabetes being the most successful product. Through the planned distribution of SciLin® we will further support patients with diabetes and will expand our position in this very promising growth market.” said Andreas Fibig, CEO of Bayer Schering Pharma AG.*

*“This agreement represents a significant step for SciGen. Working with Bayer will make Scilin® available to diabetes patients throughout China, a growing and increasingly important market. ”, said Adam Allerhand Chairman and CEO of SciGen.*

According to current data, there are approximately 40 million diabetic patients in China. Insulin is the fastest growing segment of the Chinese diabetes market in China with projected annual growth rates of more than 40 percent.

### **About SciGen**

SciGen Ltd is 90.5% owned by Bioton S.A. It is a progressive biopharmaceutical company involved in co-developing and marketing genetically engineered biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes a third generation Hepatitis B Vaccine and therapeutics such as rhuman Growth Hormone, rhuman Insulin, GCSF and Interferon Alpha 2b.

SciGen has acquired the rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biosimilar products, which allows for faster entry into the market, as the biogeneric products have undergone much of the clinical development and trials required to bring new drugs to market. This minimises the risks associated with early stage product development.

SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's major strength lies in its ability to recognise the potential of new products in their early stages of development. Through joint collaboration with its strategic partners, SciGen uses its extensive expertise in regulatory and clinical environments, in conjunction with marketing and promotional infrastructure, to bring to market products which will have significant long-term benefit.

SciGen's business was established in 1988. SciGen is a Singapore biotechnology company, publicly listed on the Australian Stock Exchange (ASX code SIE). SciGen's headquarters is in Singapore and it also has subsidiary companies and offices in the Australia, S.Korea, Vietnam, China, India, Israel and Philippines, distribution channels in Taiwan, China, India, Pakistan, Thailand and Indonesia, manufacturing facilities in Israel, India and China. Bioton S.A is the supplier of Insulin to SciGen.

<b>For further information: Company - Investor Relations</b>	<b>Company</b>
Ms. Gillian Dunlop SciGen (Australia) Pty Ltd +61 2 9485 1800 Email: <a href="mailto:gdunlop@scigen.com.au">gdunlop@scigen.com.au</a>	Adam Allerhand Chairman & CEO SciGen Ltd +65 6779 6638